NAD+ dosing schedule
> Updated:
Human schedule
A subcutaneous reference generalized from longevity-practice protocols; controlled clinical data on NAD+ are limited. Start at a lower dose to assess tolerance, then increase if needed.
This is a concise reference to regimens described for adults; it is not an individual prescription.
NAD+ injection schedule in these protocols starts with a small dose to assess tolerance and then increases: NAD+'s short half-life in blood is why injections are given several times a week rather than once a month.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (tolerance) | 50 mg subcutaneously | Starting dose |
| Loading, 4–8 weeks | 50–100 mg, 2–3× weekly | Increase if tolerated |
| Maintenance | 100 mg, 1–2× weekly | Maximum in this schedule |
Practical dosing and effect details
The pharmacokinetics of NAD+ in humans were studied by Grant and colleagues (Frontiers in Aging Neuroscience, 2019): participants received a 6-hour intravenous infusion at 3 micromol per minute. The researchers found that NAD+ is cleared from plasma at almost the same rate it is infused: a measurable rise in urinary metabolites appeared only at the 6-hour mark, not right away. That fits the logic of the schedule on this page: instead of one large dose, the protocol starts at 50 mg to assess tolerance, then 50-100 mg 2-3x weekly across a 4-8 week loading phase, and 100 mg 1-2x weekly for maintenance, meaning regular smaller doses rather than an occasional large volume. Grant's study used an intravenous route, while the table above describes subcutaneous administration; these are two different routes, and a direct dose translation between them has not been established. This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.